Comprehensive Financial Consultants Institutional Inc. Boosts Stake in IQVIA Holdings Inc. $IQV

Key Points

• Comprehensive Financial Consultants Institutional Inc. increased its stake in IQVIA Holdings Inc. by 40.2%, now owning 14,021 shares valued at $2.21 million.
• Several hedge funds, including Brighton Jones LLC and Merit Financial Group LLC, also significantly boosted their positions in IQVIA, indicating strong institutional interest in the company.
• IQVIA's recent quarterly earnings reported an EPS of $2.81, surpassing analyst estimates, and the company has set a guidance for FY 2025 of 11.750-12.050 EPS.

Comprehensive Financial Consultants Institutional Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 40.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 14,021 shares of the medical research company's stock after purchasing an additional 4,023 shares during the period. Comprehensive Financial Consultants Institutional Inc.'s holdings in IQVIA were worth $2,210,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after buying an additional 2,537 shares during the period. Merit Financial Group LLC boosted its position in IQVIA by 59.4% in the 1st quarter. Merit Financial Group LLC now owns 6,845 shares of the medical research company's stock valued at $1,207,000 after buying an additional 2,552 shares during the period. Independence Bank of Kentucky boosted its position in IQVIA by 42.9% in the 1st quarter. Independence Bank of Kentucky now owns 580 shares of the medical research company's stock valued at $102,000 after buying an additional 174 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its position in IQVIA by 17.0% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 8,637 shares of the medical research company's stock valued at $1,523,000 after buying an additional 1,254 shares during the period. Finally, Park Avenue Securities LLC boosted its position in IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after buying an additional 1,562 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 1.2%

NYSE IQV opened at $206.84 on Monday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $35.16 billion, a PE ratio of 29.93, a P/E/G ratio of 2.27 and a beta of 1.32. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $237.34. The firm's fifty day moving average is $187.90 and its two-hundred day moving average is $167.44.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the business posted $2.64 earnings per share. IQVIA's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and raised their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Barclays raised their price objective on shares of IQVIA from $185.00 to $200.00 and gave the company an "equal weight" rating in a report on Thursday. Robert W. Baird raised their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Finally, UBS Group raised their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $230.32.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.